Focal adhesion kinase FAK interplays with ROR1 in the aggressiveness of chronic lymphocytic leukemia.
A newly identified cancer survival pathway in leukemia could be blocked alongside existing targeted drugs to overcome treatment resistance.
This BMC Medicine study characterizes a novel FAK-ROR1 signaling axis in CLL cells that contributes to disease aggressiveness through pro-survival and migratory signaling. The work identifies FAK as a tractable target in CLL, particularly relevant as a combination partner with existing BTK inhibitor therapy to overcome microenvironmental resistance.
What the study was
- Study design
- Preclinical mechanistic study
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- BMC Med
Why it surfaced
BMC Medicine is a high-impact open journal; FAK-ROR1 axis is a novel CLL resistance mechanism; potential combination therapeutic target; from established Padova/Trento CLL research group.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.